Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

William Shannon, PhD

Founder and President
BioRankings, LLC
Member of the Healthcare Council

William Shannon, PhD, is an Associate Professor of Biostatistics at Washington University School of Medicine, since 1995; and Founder and President of BioRankings, a pharma IT firm, since January 2007. Dr. Shannon has over 20 years of applied biostatistical expertise in biomedical, pharmaceutical, and biotech research. He has 100 peer-reviewed publications in areas such as oncology, genetics, cardiology, pulmonology infectious disease, sleep medicine, health care delivery, statistics, and other areas. By making complex biostatistical ideas understandable, Dr. Shannon can help companies gain insight on the strengths and weaknesses of pre-clinical data and clinical trials that may impact a company's long term viability, and understanding of statistical data to protect investment. (This is me - Update Profile)


Employment History
2007 - present Founder and President
BioRankings, LLC
1995 - present Associate Professor (Tenured)
Washington University in St. Louis-School of Medicine

GLG Study Groups with William Shannon, PhD(?)

Study Group Name Members
Biostatisticians (US) 265
Biostatisticians 394

GLG NewsSM Analyses by William Shannon, PhD(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
Eli Lilly's Personal Medicine Goal | 11-27-2008
Analysis of: Personal medicine is goal of Eli Lilly & Co. | www.azcentral.com
Author: William Shannon, PhD, Founder and President, BioRankings, LLC

The Chairman of Eli Lilly announcing that personalized medicine (e.g., pharmacogenetics) is a major shift in strategy for big pharma could impact in a significant way the market share for new drugs and the amount of money for research needed to bring a targeted therapy to market. If this strategy is...

Dealing with publication bias using the 'file drawer' scenario. | 10-28-2008
Analysis of: Many Trial Reports on FDA-Approved Drugs Go Unpublished | www.washingtonpost.com
Author: William Shannon, PhD, Founder and President, BioRankings, LLC

In this meta-analysis, the authors looked at the number of studies, if any, per new drug application with the FDA that got published, at what time, and how much information they released. They concluded that there is strong evidence of publication bias in what the drug companies will make public, with...

Is Biodel's argument to drop the India data from analysis valid? | 10-09-2008
Analysis of: Biodel Releases Preliminary Phase III Clinical Trials for VIAject | www.fiercebiotech.com
Author: William Shannon, PhD, Founder and President, BioRankings, LLC

Biodel’s September 8th announcement of the Phase III non-inferiority trial results for VIAject at the 44th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Rome left many investors wary of the legitimacy of the data that was presented. The study, which was originally conducted...

Review of Statistical Conclusions of National Trends in Psychotherapy by Office-Based Psychiatrists | 08-20-2008
Analysis of: National Trends in Psychotherapy by Office-Based Psychiatrists | archpsyc.ama-assn.org
Author: William Shannon, PhD, Founder and President, BioRankings, LLC

An August 2008 study analyzing the National Ambulatory Medical Care Survey (NAMCA) database shows a significant decrease in the amount of psychotherapy that psychiatrists are providing for their patients, while at the same time possibly showing an increase in medications prescribed. This correlation...

View All GLG News SM Analyses by William Shannon, PhD

GLG InstituteSM Seminars with William Shannon, PhD(?)

 
William Shannon, PhD has not participated in any GLGi Seminars.
View all GLG InstituteSM Seminars in Healthcare

Request a project with William Shannon, PhD









Note: GLG Experts do not provide personal medical advice, diagnosis or treatment through this site.

GLG's 750+ Clients Include:

40 of the leading 50
global mutual funds
15 of the leading 20
global banks
8 of the leading 10
private equity firms
90%+ client subscription renewal rate

Analytics


Generated at 2008-12-02T17:45:17.163